|
KMID : 1188320130070040406
|
|
Gut and Liver
2013 Volume.7 No. 4 p.406 ~ p.410
|
|
|
Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea
|
|
Moon Ji-Yoon
Kim Gwang-Ha
You Hyun-Seok
Lee Bong-Eun
Ryu Dong-Yeop
Cheong Jae-Hoon
Jung Jung-Im
Jeong Jae-Hoon
Song Chul-Soo
Song Geun-Am
|
|
|
Abstract
|
|
|
Background/Aims:Several rescue therapies have been recommended to eradicate Helicobacter pylori infection in patients with a failure of first-line eradication therapy, but they still fail in more than 20% of cases. The aim of this study was to evaluate the efficacy and safety of levofloxacin, metronidazole, and lansoprazole (LML) triple therapy relative to quadruple therapy as a second-line treatment.
Methods:In total, 113 patients who failed first-line triple therapy for H. pylori infection were randomly assigned to two groups: LML for 7 days and tetracycline, bismuth subcitrate, metronidazole and lansoprazole (quadruple) for 7 days.
Results:According to intention-to-treat analysis, the infection was eradicated in 38 of 56 patients (67.9%) in the LML group and 48 of 57 (84.2%) in the quadruple group (p=0.042). Per-protocol analysis showed successful eradication in 38 of 52 patients (73.1%) from the LML group and 48 of 52 (92.3%) from the quadruple group (p=0.010). There were no significant differences in the adverse effects in either treatment group.
Conclusions:LML therapy is less effective than quadruple therapy as a second-line treatment for H. pylori infection. Therefore, quadruple therapy should be considered as the primary second-line strategy for patients experiencing a failure of first-line H. pylori therapy in Korea.
|
|
|
KEYWORD
|
|
|
Helicobacter pylori, Therapeutics, Failure, Levofloxacin, Metronidazole
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|
|